Protara Therapeutics is trading 5.15% lower at $2.48 as hotter-than-expected September inflation weighs on equities and raises interest-rate concerns. - No clear company-specific announcement has been identified to explain the decline. - Biotech shares were also under pressure in the previous session. - The move points to broader market sentiment rather than a confirmed company catalyst.